Vericel Corporation

VCEL

US92346J1088

Pharmaceuticals

Real-time Estimate Cboe BZX Other stock markets 12:30:12 2024-06-27 pm EDT			5-day change	1st Jan Change
47.12 ^USD	+2.97%		+5.75%	+32.63%

Jun. 20	TD Cowen Initiates Vericel at Buy With $55 Price Target	MT
Jun. 14	Vericel Insider Sold Shares Worth $1,526,350, According to a Recent SEC Filing	MT

Aastrom Biosciences, Inc. Announces Resignation of Ronnda Bartel as Chief Scientific Officer

January 14, 2014 at 05:08 pm EST

Effective as of January 1, 2014, Ronnda Bartel, will step down from her role as the Chief Scientific Officer of Aastrom Biosciences, Inc. Dr. Bartel will continue as a consultant.

Latest news about Vericel Corporation

TD Cowen Initiates Vericel at Buy With $55 Price Target	Jun. 20	MT
Vericel Insider Sold Shares Worth $1,526,350, According to a Recent SEC Filing	Jun. 14	MT
Vericel Insider Sold Shares Worth $499,900, According to a Recent SEC Filing	May. 21	MT
Vericel Q1 Loss Narrows, Revenue Increases; 2024 Outlook Lifted -- Shares Rise Pre-Bell	May. 08	MT
Earnings Flash (VCEL) VERICEL CORPORATION Posts Q1 Revenue $51.3M, vs. Street Est of $49.1M	May. 08	MT
Transcript : Vericel Corporation, Q1 2024 Earnings Call, May 08, 2024	May. 08
Vericel Corporation Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 08	CI
Vericel Corporation Provides Earnings Guidance for the Year 2024	May. 08	CI
Vericel Insider Sold Shares Worth $1,593,550, According to a Recent SEC Filing	Apr. 19	MT
Vericel Insider Sold Shares Worth $1,552,075, According to a Recent SEC Filing	Mar. 15	MT
Vericel Insider Sold Shares Worth $352,047, According to a Recent SEC Filing	Mar. 13	MT
Vericel Insider Sold Shares Worth $367,853, According to a Recent SEC Filing	Mar. 11	MT
Truist Securities Raises Vericel's Price Target to $54 From $51, Keeps Buy Rating	Mar. 01	MT
HC Wainwright Adjusts Price Target on Vericel to $53 From $46, Keeps Buy Rating	Mar. 01	MT
Vericel Q4 EPS, Revenue Increase; Issues 2024 Outlook -- Shares Rise Pre-Bell	Feb. 29	MT
Vericel Corporation Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 29	CI
Transcript : Vericel Corporation, Q4 2023 Earnings Call, Feb 29, 2024	Feb. 29
Vericel Corporation Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Feb. 29	CI
Vericel Corporation Provides Earnings Guidance for the Fiscal Year 2024	Feb. 29	CI
Earnings Flash (VCEL) VERICEL CORPORATION Reports Q4 Revenue $65M, vs. Street Est of $64M	Feb. 29	MT
North American Morning Briefing : Fed's Preferred -2-	Feb. 29	DJ
Vericel Insider Sold Shares Worth $1,677,200, According to a Recent SEC Filing	Feb. 16	MT
North American Morning Briefing : Intel Drags Down -2-	Jan. 26	DJ
Vericel Insider Sold Shares Worth $334,775, According to a Recent SEC Filing	Jan. 24	MT
Vericel Insider Sold Shares Worth $1,280,375, According to a Recent SEC Filing	Jan. 19	MT

Vericel Corporation is a fully-integrated, commercial-stage biopharmaceutical company. The Company is a provider of advanced therapies for the sports medicine and severe burn care markets. It markets three products in the United States. MACI (autologous cultured chondrocytes on porcine collagen membrane) is an autologous-cellularized scaffold product indicated for the repair of symptomatic, single or multiple full-thickness cartilage defects of the knee with or without bone involvement in adults. Epicel (cultured epidermal autografts) is a permanent skin replacement for the treatment of patients with deep dermal or full thickness burns greater than or equal to 30% of total body surface area. The Company also holds a license for North American rights to NexoBrid (anacaulase-bcdb), a biological orphan product containing proteolytic enzymes, which is indicated for the removal of eschar in adults with deep partial-thickness and/or full-thickness burns.

Sector

Pharmaceuticals

Calendar

2024-07-30 - Q2 2024 Earnings Release (Projected)

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Ratings for Vericel Corporation

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

45.76 USD

Average target price

55.33 USD

Spread / Average Target

+20.92%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Biopharmaceuticals

	1st Jan change	Capi.
VERICEL CORPORATION	+32.63%	2.22B
CSL LIMITED	+2.97%	94.74B
SAMSUNG BIOLOGICS CO.,LTD.	-3.68%	37.28B
BIOGEN INC.	-11.78%	32.68B
UCB	+74.21%	27.72B
BIOMARIN PHARMACEUTICAL INC.	-13.86%	16.19B
INCYTE CORPORATION	-2.25%	13.88B
BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD.	-12.21%	11.58B
ALTEOGEN INC.	+188.83%	10.92B
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD.	-53.94%	9.54B

Biopharmaceuticals

Vericel Corporation

Equities

VCEL

US92346J1088

Pharmaceuticals

Aastrom Biosciences, Inc. Announces Resignation of Ronnda Bartel as Chief Scientific Officer

Latest news about Vericel Corporation

Chart Vericel Corporation

Company Profile

Income Statement Evolution

Ratings for Vericel Corporation

Analysts' Consensus

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Biopharmaceuticals